» Articles » PMID: 26679003

A Strategy for Residual Error Modeling Incorporating Scedasticity of Variance and Distribution Shape

Overview
Publisher Springer
Specialty Pharmacology
Date 2015 Dec 19
PMID 26679003
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Nonlinear mixed effects models parameters are commonly estimated using maximum likelihood. The properties of these estimators depend on the assumption that residual errors are independent and normally distributed with mean zero and correctly defined variance. Violations of this assumption can cause bias in parameter estimates, invalidate the likelihood ratio test and preclude simulation of real-life like data. The choice of error model is mostly done on a case-by-case basis from a limited set of commonly used models. In this work, two strategies are proposed to extend and unify residual error modeling: a dynamic transform-both-sides approach combined with a power error model (dTBS) capable of handling skewed and/or heteroscedastic residuals, and a t-distributed residual error model allowing for symmetric heavy tails. Ten published pharmacokinetic and pharmacodynamic models as well as stochastic simulation and estimation were used to evaluate the two approaches. dTBS always led to significant improvements in objective function value, with most examples displaying some degree of right-skewness and variances proportional to predictions raised to powers between 0 and 1. The t-distribution led to significant improvement for 5 out of 10 models with degrees of freedom between 3 and 9. Six models were most improved by the t-distribution while four models benefited more from dTBS. Changes in other model parameter estimates were observed. In conclusion, the use of dTBS and/or t-distribution models provides a flexible and easy-to-use framework capable of characterizing all commonly encountered residual error distributions.

Citing Articles

Population Pharmacokinetics of Sotorasib in Healthy Subjects and Advanced Solid Tumor Patients Harboring a KRAS Mutation from Phase 1 and Phase 2 Studies.

Nagase M, Houk B, Vuu I, Cardona P, Dutta S, Lin C AAPS J. 2025; 27(1):26.

PMID: 39806205 DOI: 10.1208/s12248-024-01013-6.


Exposure-response modeling of liver fat imaging endpoints in non-alcoholic fatty liver disease populations administered ervogastat alone and co-administered with clesacostat.

Hughes J, Amin N, Wojciechowski J, Vourvahis M CPT Pharmacometrics Syst Pharmacol. 2024; 14(2):317-330.

PMID: 39564924 PMC: 11812935. DOI: 10.1002/psp4.13275.


A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trial.

Puszkiel A, You B, Payen L, Lopez J, Guitton J, Rousset P Cancer Chemother Pharmacol. 2023; 91(5):413-425.

PMID: 37010549 DOI: 10.1007/s00280-023-04520-z.


Population Pharmacokinetics of Meropenem in Critically Ill Korean Patients and Effects of Extracorporeal Membrane Oxygenation.

Lee D, Kim H, Park S, Kim H, Lee S, Kim Y Pharmaceutics. 2021; 13(11).

PMID: 34834278 PMC: 8625191. DOI: 10.3390/pharmaceutics13111861.


Predicting ewe body condition score using adjusted liveweight for conceptus and fleece weight, height at withers, and previous body condition score record.

Semakula J, Corner-Thomas R, Morris S, Blair H, Kenyon P Transl Anim Sci. 2021; 5(3):txab130.

PMID: 34790893 PMC: 8592046. DOI: 10.1093/tas/txab130.


References
1.
Oberg A, Davidian M . Estimating data transformations in nonlinear mixed effects models. Biometrics. 2000; 56(1):65-72. DOI: 10.1111/j.0006-341x.2000.00065.x. View

2.
Jonsson S, Davidse A, Wilkins J, van der Walt J, Simonsson U, Karlsson M . Population pharmacokinetics of ethambutol in South African tuberculosis patients. Antimicrob Agents Chemother. 2011; 55(9):4230-7. PMC: 3165318. DOI: 10.1128/AAC.00274-11. View

3.
Lindbom L, Pihlgren P, Jonsson E, Jonsson N . PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005; 79(3):241-57. DOI: 10.1016/j.cmpb.2005.04.005. View

4.
Petersson K, Hanze E, Savic R, Karlsson M . Semiparametric distributions with estimated shape parameters. Pharm Res. 2009; 26(9):2174-85. DOI: 10.1007/s11095-009-9931-1. View

5.
Lindemalm S, Savic R, Karlsson M, Juliusson G, Liliemark J, Albertioni F . Application of population pharmacokinetics to cladribine. BMC Pharmacol. 2005; 5:4. PMC: 1079880. DOI: 10.1186/1471-2210-5-4. View